Sumitomo Pharma Co., Ltd. (TYO:4506)
Japan · Delayed Price · Currency is JPY 1,345.00
+50.00 (3.86%)
Aug 10, 2026, 3:30 PM JST
Sumitomo Pharma Financials Overview
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 474,787 | 453,294 | 398,832 | 314,558 | 555,544 | 560,035 |
Revenue Growth | 14.09% | 13.66% | 26.79% | -43.38% | -0.80% | 8.54% |
Gross Profit Gross Profit Growth | 261,084 | 256,893 | 245,502 | 187,981 | 376,625 | 402,908 |
Operating Income Operating Income Growth | 49,514 | 52,801 | 17,770 | -355,136 | -126,349 | 59,967 |
Net Income Net Income Growth | 112,656 | 106,865 | 23,634 | -314,969 | -74,512 | 56,413 |
Earnings Per Share EPS Growth | 276.88 | 268.99 | 59.49 | -792.79 | -187.55 | 141.99 |
EPS Growth | 481.93% | 352.17% | - | - | - | 0.34% |
| Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Pharmaceuticals - North America Pharmaceuticals - North America Growth | 337,923 | 251,814 | 159,037 | 328,467 | 319,790 |
Pharmaceuticals - Japan Pharmaceuticals - Japan Growth | 92,365 | 99,838 | 114,657 | 126,164 | 149,976 |
Pharmaceuticals - Asia Pharmaceuticals - Asia Growth | 23,006 | 47,180 | 40,864 | - | - |
Total Total Growth | 453,294 | 398,832 | 314,558 | 555,544 | 560,035 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 76,640 | 44,310 | 36,288 | 29,047 | 143,478 | 202,984 |
Total Debt Total Debt Growth | 160,658 | 224,216 | 314,246 | 427,864 | 346,372 | 284,544 |
Net Cash (Debt) Net Cash Growth | -84,018 | -179,906 | -277,958 | -398,817 | -202,894 | -81,560 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -206.50 | -452.83 | -699.64 | -1003.84 | -510.69 | -205.29 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 64,464 | 71,715 | 16,500 | -241,893 | 11,937 | 31,239 |
Capital Expenditures CapEx Growth | -3,798 | -4,609 | -8,498 | -10,771 | -8,467 | -7,347 |
Free Cash Flow Free Cash Flow Growth | 60,666 | 67,106 | 8,002 | -252,664 | 3,470 | 23,892 |
Free Cash Flow Growth | 80.06% | 738.62% | - | - | -85.48% | -81.56% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 54.99% | 56.67% | 61.56% | 59.76% | 67.79% | 71.94% |
Operating Margin | 10.43% | 11.65% | 4.46% | -112.90% | -22.74% | 10.71% |
Pretax Margin | 22.47% | 22.14% | 4.42% | -102.72% | -8.63% | 14.81% |
Profit Margin | 23.73% | 23.57% | 5.93% | -100.13% | -13.41% | 10.07% |
FCF Margin | 12.78% | 14.80% | 2.01% | -80.32% | 0.63% | 4.27% |
| Fiscal Year | FY 2023 | FY 2022 |
|---|---|---|
| Period Ending | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 21.000 | 28.000 |
Dividend Per Share Growth | -25.00% | 0% |
Dividend Yield | 2.59% | 2.37% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 4.86 | 7.72 | 12.26 | - | - | 8.51 |
Forward PE | 6.78 | 9.45 | 19.16 | 20.73 | 20.73 | 11.10 |
P/FCF Ratio | 9.95 | 12.29 | 36.19 | - | 92.74 | 20.09 |
PS Ratio | 1.27 | 1.82 | 0.73 | 0.50 | 0.58 | 0.86 |